NanoViricides highlights its antiviral drug NV-387 as a potential solution during a deadly hantavirus outbreak on a cruise ship. NV-387 has completed Phase I trials showing safety and effectiveness against multiple viruses, including those spreading via respiratory routes like the Andes hantavirus. The drug targets viral entry mechanisms common to over 90% of pathogenic viruses, offering an advantage over vaccines and antibody therapies. NanoViricides aims to position NV-387 as a rapid first-response treatment to control outbreaks early and protect close contacts prophylactically.
Taiwan Semiconductor Manufacturing Company (TSMC) reported a 23.4% increase in second-quarter profit from the previous quarter, surpassing analyst estimates. The company's net income reached NT$706.56 billion ($39.45 billion), a record high for the f...
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
